Zentiva Sale Wipes More Than A Third Off Sanofi Generics

Divesting its Zentiva branded generics business in Europe in October last year reduced Sanofi's first-quarter 2019 Generics sales by more than a third to EUR282m; but on a 'constant structure' basis, adjusted for the divestment, Generics sales grew by 3.6% to account for just over 3% of Sanofi's group turnover.